One-Year Study of S1B-509 vs Placebo for Weight Loss

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

210

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

June 15, 2027

Study Completion Date

December 15, 2027

Conditions

Obesity

Interventions

DRUG

S1B-509 low dose

S1B-509 has multiple neurotransmitter activities

DRUG

Placebo

matched pills to S1B-509

DRUG

S1B-509 High Dose

S1B-509 has multiple neurotransmitter activities

All Listed Sponsors

lead

S1 Biopharma, Inc.

INDUSTRY